within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G02B_ContraceptivesForTopicalUse.G02BB01_VaginalRingWithProgestogenAndEst;

model VaginalRingWithProgestogenAndEst
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 9.722222222222222e-07,
    adminDuration = 600,
    adminMass = 11.7 / 1000000,
    adminCount = 1,
    Vd = 0.002,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>VaginalRingWithProgestogenAndEstrogen</td></tr><tr><td>ATC code:</td><td>G02BB01</td></tr><td>route:</td><td>vaginal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>The vaginal ring containing progestogen and estrogen is a contraceptive device designed for intravaginal administration delivering a combination of an estrogen (usually ethinylestradiol) and a progestogen (such as etonogestrel). It provides effective reversible contraception and is approved for use by women of reproductive age.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical healthy adult female user, as reported for the etonogestrel/ethinylestradiol vaginal ring (e.g., NuvaRing).</p><h4>References</h4><ol><li><p>Nelson, AL (2019). Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method. <i>Expert review of clinical pharmacology</i> 12(10) 953–963. DOI:<a href=\"https://doi.org/10.1080/17512433.2019.1669448\">10.1080/17512433.2019.1669448</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31526281/\">https://pubmed.ncbi.nlm.nih.gov/31526281</a></p></li><li><p>Thakur, K, et al., &amp; Polak, S (2024). Development and verification of mechanistic vaginal absorption and metabolism model to predict systemic exposure after vaginal ring and gel application. <i>British journal of clinical pharmacology</i> 90(6) 1428–1449. DOI:<a href=\"https://doi.org/10.1111/bcp.16029\">10.1111/bcp.16029</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38450818/\">https://pubmed.ncbi.nlm.nih.gov/38450818</a></p></li><li><p>Shaaban, MM (1991). Contraception with progestogens and progesterone during lactation. <i>The Journal of steroid biochemistry and molecular biology</i> 40(4-6) 705–710. DOI:<a href=\"https://doi.org/10.1016/0960-0760(91)90294-f\">10.1016/0960-0760(91)90294-f</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1835650/\">https://pubmed.ncbi.nlm.nih.gov/1835650</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.G.G02BB01 folded in (Drugs.ATC removed)</li><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end VaginalRingWithProgestogenAndEst;
